pT342-C5a1 (phospho-Complement C5a Receptor 1 Antibody)

NEW

Preview: Agonist-induced Threonine342 phosphorylation of the Complement C5a Receptor 1

Preview: Analysis of dose-dependent Complement C5a Receptor 1 phosphorylation using three phosphosite-specific antibodies

Agonist-induced Threonine342 phosphorylation of the Complement C5a Receptor 1

Analysis of dose-dependent Complement C5a Receptor 1 phosphorylation using three phosphosite-specific antibodies

$ 375.00 *

Prices plus VAT plus shipping costs

Ready to ship today,
Delivery time appr. 5-8 days

Order number: 7TM0032E
Content: 100 µl
Host: Rabbit

Threonine342 (T342) is a major phosphorylation site of the C5a1 receptor. The pT342-C5a1... more

Close menu

Threonine342 (T342) is a major phosphorylation site of the C5a1 receptor. The pT342-C5a1 antibody detects phosphorylation in response to high- and low-efficacy agonists but not after PKC activation. T342 phosphorylation is a key regulator of C5a1 desensitization, β-arrestin recruitment and internalization.

Available downloads:

Alternative Names C5a1, C5AR1, Complement C5a Receptor 1, C5a Anaphylatoxin... more

Close menu

Alternative Names	C5a1, C5AR1, Complement C5a Receptor 1, C5a Anaphylatoxin Chemotactic Receptor 1
IUPHAR Target ID	32
UniProt ID	P21730
Western Blot (WB)	1:1000
Immunocytochemistry (ICC)	1:200
Species Reactivity	Human
Host / Isotype	Rabbit / IgG
Class	Polyclonal
Immunogen	A synthetic phosphopeptide derived from human C5a1 around the phosphorylation site of Thr342.
Form	Liquid
Purification	Antigen affinity chromatography
Storage buffer	Dulbecco's PBS, pH 7.4, with 150 mM NaCl, 0.02% sodium azide
Storage conditions	short-term 4°C, long-term -20°C

Figure 1. Agonist-induced Threonine342 phosphorylation of the Complement C5a Receptor 1.... more

Close menu

Figure 1. Agonist-induced Threonine342 phosphorylation of the Complement C5a Receptor 1. Upper panel, HEK293 cells stably expressing the Complement C5a Receptor 1 (C5a1) were either not exposed or exposed to 1 µM specific Complement C5a receptor agonist CO28 or 0.1 μM PMA (Phorbol 12-Myristate 13-Acetate) for 30 minutes. Cells were lysed and immunoblotted with the anti-pT342-C5a1 antibody (7TM0032E) at a dilution of 1:1000. Lower panel, blot was stripped and reprobed with the phosphorylation-independent anti-C5a1 antibody (7TM0032N-WB) at a dilution of 1:1000 to confirm equal loading of the gel.

Figure 2. Analysis of dose-dependent Complement C5a Receptor 1 phosphorylation using three phosphosite-specific antibodies. Upper three panels, HEK293 cells stably expressing the Complement C5a Receptor 1 (C5a1) were either not exposed or exposed to decreasing concentrations of specific Complement C5a receptor agonist CO28 ranging from 100 µM to 10 nM for 30 minutes. Cells were lysed and immunoblotted with the anti-pT336-C5a1 antibody (7TM0032C) or anti-pS338/pT339-C5a1 antibody (7TM0032D) or anti-pT342-C5a1 antibody (7TM0032E) at a dilution of 1:1000. Lower panel, blot was stripped and reprobed with the phosphorylation-independent anti-C5a1 antibody (7TM0032N-WB) at a dilution of 1:1000 to confirm equal loading of the gel.